Roxane Labs makes recently approved IBS treatment available to ship
COLUMBUS, Ohio — On Thursday Roxane Laboratories announced that its alosetron hydrochloride tablets — a generic version of irritable bowel syndrome treatment Lotronex — was available in 0.5- and 1-mg strength.
The U.S. Food and Drug Administration approved Roxane’s abbreviated new drug application for the medication on May 4, making an approximately $86 million annual market available to the company.
The news of the availability of Roxane’s IBS drug comes the same day that the FDA approved two new brand-name IBS treatments, Patheon Pharmaceuticals’ Viberzi and Salix Pharmaceuticals’ Xifaxan.
NABP announces general registration date for .pharmacy domains
MOUNT PROSPECT, Illi. — Some online pharmacy sites will soon be able to point visitors to their .pharmacy domain names. The National Association of Boards of Pharmacy (NABP) announced Thursday that .pharmacy domains will enter general registration for pharmacies and related organizations starting June 3.
The NABP introduced the pharmacy-centered Top-Level Domain (TLD) in 2014 as a way for consumers to clearly distinguish legitimate online pharmacy resources from potentially unsafe and illegal sites. NABP’s review of about 11,000 sites selling prescriptions drugs found that 96% of them skirt pharmacy standards and laws. Since introducing the TLD, NABP has approved the requests of some 300 entities who applied during the limited registration period for a .pharmacy domain.
Those interested in a .pharmacy domain must apply with an application fee and documentation showing that the organization’s site complies with NABP standards, as well as all the content from the proposed site. Organizations who are approved by the Verified Internet Pharmacy Practice Sites (VIPPS) and its veterinary counterpart (Vet-VIPPS) do not need to submit an application. More information about the .pharmacy TLD can be found at safe.pharmacy.
Camber intros generic Abilify
PISCATAWAY, N.J. — Camber Pharmaceuticals on Thursday announced that it had launched antipsychotic drug aripiprazole — a generic version of Abilify — in 2-, 5-, 10-, 15-, 20- and 30-mg strength tablets.
Aripiprazole is used to treat schizophrenia, which affects about 1% of the population, and bipolar disorder. The FDA approved the first round of the generic in late April.
Loading Post Please Wait...